NCT00136981

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 800 (planned)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with heterozygous familial hypercholesterolemia

Detailed description

For additional information please call: 1-800-718-1021

Conditions

• Hypercholesterolemia, Familial
• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	torcetrapib/atorvastatin
DRUG	atorvastatin

Timeline

• Start date: 2003-12-01
• Completion: 2006-11-01
• First posted: 2005-08-29
• Last updated: 2015-04-22

Locations

34 sites across 8 countries: United States, Canada, Czechia, Finland, France, Italy, Netherlands, South Africa